Hai-Genti

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

Retrieved on: 
Wednesday, September 14, 2022

CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company's platform technology. The abstract, entitled "Finely Controlled IL-2 Signal in Engineered Human Tregs utilizing a Chemically Induced Signaling Complex (CISC)" will be presented at The Promise of IL-2 Conference in Paris, France on September 16, 2022.

Key Points: 
  • By way of background, Tregsare crucially important in addressing many diseases driven by uncontrolled autologous and allogeneic reactivity.
  • Further, interleukin-2 (IL-2) is the key cytokine for supporting Tregs homeostasis and its functional scarcity underpins many autoimmune diseases.
  • For Tregs therapeutics, IL-2 is essential to support in vivo Tregs stability, proliferation, and persistence, and hence, potency.
  • The company also has a collaboration with Bristol Myers Squibb for the development of Treg therapies for inflammatory bowel diseases.